Patients interested in weight management can review our dedicated medical weight loss resources below
Systemic actions of SGLT2 inhibition on chronic mTOR activation as a shared pathogenic mechanism between alzheimer's disease and diabetes
In a published Phase 2 trial (48 weeks), adults with obesity who took retatrutide lost, on average, more weight at higher doses, with the 12 mg group showing 24.2% average weight change at 48 weeks (compared with 2.1% in the placebo group)
8 Based on limited research, tirzepatide has not been shown to affect cardiovascular outcomes or reduce overall mortality compared with usual care
When levels begin to drop during perimenopause, our bodies can start to changeeven if our diet and exercise routines havent
doi:10.1001/archderm.136.3.323 10Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P